Horowitz John D, Heresztyn Tamila
Cardiology Unit, Queen Elizabeth Hospital, University of Adelaide, 28 Woodville Road, Woodville South, SA, Australia.
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 May 15;851(1-2):42-50. doi: 10.1016/j.jchromb.2006.09.023. Epub 2006 Oct 11.
Recent studies among patients including those with known coronary disease demonstrate that small elevations in asymmetric dimethylarginine (ADMA) concentrations in plasma are predictive of adverse outcomes. The precision of current methodologies for quantitation of ADMA such as HPLC, MS and ELISA is discussed with respect to many reports which appear to over-estimate ADMA levels and quote broad concentration ranges. While plasma ADMA concentrations tend to increase with age, the mean for a healthy population is between 0.4 and 0.6 microM. ADMA levels may fluctuate in normal subjects, and this needs to be considered in light of the relatively small differences in ADMA concentration between healthy normal subjects and patients.
近期针对包括已知患有冠心病患者在内的研究表明，血浆中不对称二甲基精氨酸（ADMA）浓度的小幅升高可预测不良后果。关于许多似乎高估ADMA水平并引用宽泛浓度范围的报告，讨论了诸如高效液相色谱法（HPLC）、质谱法（MS）和酶联免疫吸附测定法（ELISA）等当前ADMA定量方法的准确性。虽然血浆ADMA浓度往往会随年龄增长而升高，但健康人群的平均值在0.4至0.6微摩尔之间。正常受试者的ADMA水平可能会波动，鉴于健康正常受试者与患者之间ADMA浓度的差异相对较小，这一点需要加以考虑。
